Oncology What will ASCO 2026 reveal about oncology innovation’s new g... The next leaders in oncology will be the ones built to adapt in real time.
News BioMarin snaps up Alesta's lead asset for $275M BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
